Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 0.72 |
| ▸ | RXRB | P28702 | 7/20 | 0.72 |
| ▸ | RXRG | P48443 | 5/20 | 0.72 |
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082270 | 0.96 | RXRA (0.72) | RXRARXRBRXRGCES2DHODH | |
| SCHEMBL503980 | 0.91 | CES2 (0.70) | RXRARXRBRXRGCES2AKR1C3 | |
| SCHEMBL28119413 | 0.89 | CES2 (0.67) | RXRARXRBRXRGCES2AKR1C3 | |
| Hydrochloric Acid SCHEMBL7485970 | 0.89 | CES2 (0.67) | RXRARXRBRXRGCES2AKR1C3 | |
| SCHEMBL30469526 | 0.89 | RXRA (0.74) | RXRARXRBRXRGDHODHSRD5A2 | |
| SCHEMBL121358 | 0.89 | RXRA (0.69) | RXRARXRBRXRGDHODHSRD5A2 | |
| SCHEMBL25560565 | 0.89 | RXRA (0.74) | RXRARXRBRXRGDHODHSRD5A2 | |
| SCHEMBL16809141 | 0.87 | RXRA (0.62) | RXRARXRBRXRGCES2DHODH | |
| SCHEMBL545011 | 0.87 | CES2 (0.62) | RXRARXRBRXRGCES2DHODH | |
| SCHEMBL21462308 | 0.86 | RXRA (0.70) | RXRARXRBRXRGCES2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | RXRA 4171/4885RXRB 3905/4885RXRG 3806/4885 |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPM6, SCN1A | RXRA 4145/4885RXRB 3875/4885RXRG 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.